← Markets

Moderna, Inc.

MRNA · NASDAQ

Market closed$61.82$-1.33 (-2.11%)After hours $61.78 · -0.06%

Key statistics

Previous close$63.15
Open$62.19
Day high$63.28
Day low$61.06
52-week high$85.60
52-week low$22.28
Market cap24.53B
Volume4.43M
Average volume7.76M
P/E ratio-7.59
Forward P/E—
EPS-8.15
Dividend yield0.00%

Market context

Why it moved

Moderna shares declined as softer COVID-19 vaccine demand continues to weigh on the company's 2026 outlook, compounded by the UK's JCVI deferring consideration of its mRNA-1010 influenza vaccine to future seasons and broader sector profit-taking amid a weak Nasdaq week.

MarketchachaSimplywallStocktwitsDovepressStockinvest

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Moderna shares fell roughly 2% as profit-taking and valuation concerns continue to weigh on the stock following its extraordinary 48% surge in June, driven by flu vaccine optimism. The pullback extends a multi-week cooling period, with analysts at Morgan Stanley, RBC Capital, and Bank of America carrying price targets well below recent trading levels — a median Wall Street target of just $46.50 versus recent highs above $85. Eyes remain on the August 5 FDA decision for mRNA-1010, the standalone flu vaccine, and Q2 earnings due July 31, while yesterday's Phase 1 initiation of mRNA-4200, an off-the-shelf solid tumor cancer therapy, added pipeline breadth but did little to arrest the selloff.

-2.1061

July 17, 2026Moderna shares tumbled roughly 7.5%, continuing a sharp pullback from the stock's highs above $85 earlier in July, as profit-taking and valuation concerns weigh heavily following a ~48% surge in June and a broader biotech rout on Thursday. The sell-off appears driven by a combination of extended positioning ahead of Q2 earnings due July 31, persistently cautious analyst consensus — with a median price target around $46.50 well below recent trading levels — and net insider selling pressure. On a more constructive note, Moderna dosed the first U.S. participant in its Phase 1 mRNA-4200 solid tumor cancer trial today, though this early-stage pipeline milestone failed to offset the prevailing sentiment reset as investors await the critical August 5 FDA decision on its mRNA flu vaccine.

-7.5132

July 16, 2026Moderna closed modestly higher, gaining roughly 1.25%, as investors look ahead to two major catalysts: an FDA decision on its mRNA flu vaccine (mFlusiva/mRNA-1010) due by August 5 and Q2 earnings scheduled for July 31. The stock has surged over 130% year-to-date, fueled by a unanimous 9-0 FDA advisory panel vote backing the flu vaccine and a strong Q1 revenue beat of $389 million (up 260% YoY). Despite the rally, Wall Street remains divided — Piper Sandler rates it Overweight with a $77 target, while Bank of America holds an Underperform with a $38 target, and the consensus sits at "Reduce," raising valuation concerns after the stock's steep run.

1.2456

July 15, 2026Moderna edged higher, recovering alongside broader markets after a soft June CPI report cooled inflation fears and lifted sentiment across equities. The stock has surged roughly 132% year-to-date — fueled by a 48% June rally — but remains under scrutiny heading into key catalysts: an FDA decision on its mRNA flu vaccine (mRNA-1010) expected by August 5 and Q2 earnings on July 31. Analyst sentiment remains cautious with a consensus 'Reduce' rating, though Piper Sandler recently upgraded to 'overweight' with a $77 target, and the EU RSV vaccine contract win provides a near-term commercial tailwind.

0.6417

July 14, 2026Moderna shares fell nearly 2%, underperforming the broader market as a risk-off session weighed on biotech names amid renewed U.S.-Iran hostilities that sent oil prices sharply higher and rattled equity sentiment. The decline added to a pullback from Moderna's 52-week high of $85.60 reached in June, following a stunning ~48% rally that month driven by FDA advisory committee endorsement of its mRNA flu vaccine mRNA-1010 and EU RSV contract wins. Investors are now focused on two key near-term catalysts: the FDA's flu vaccine decision expected by August 5 and Q2 earnings due July 31. Analyst sentiment remains cautious—consensus is a 'Reduce' with an average target of ~$51, well below current trading levels—though Jefferies raised its target to $60 and Piper Sandler rates the stock 'Overweight' with a $77 target.

-1.8456

July 11, 2026Moderna shares plunged nearly 11% — on above-average volume — marking what appears to be the stock's worst single-day decline in roughly 11 months, despite a strong recent run that had carried shares near their 52-week high of $85.60. The selloff came after Morgan Stanley reiterated its neutral "equal weight" rating on the stock, even as the firm raised its price target from $33 to $39, citing cautious optimism around COVID/flu vaccine sales and the individualized cancer therapy Intismeran. The muted rating — paired with a consensus Wall Street view of "Reduce" and an average target of ~$38 — underscored a persistent disconnect between Moderna's elevated share price and analyst conviction, with Q2 results now scheduled for July 31 serving as the next key catalyst.

-10.8281

July 10, 2026Moderna gained nearly 4%, rebounding strongly amid a buoyant biotech sector even as Morgan Stanley reiterated its neutral 'equal-weight' rating — albeit with a raised price target of $39. Investor sentiment was also lifted by Moderna's announcement of a Q2 earnings call scheduled for July 31, the appointment of former Biogen CFO Michael McDonnell to its board, and its confirmed £1 billion, 10-year R&D commitment in the UK. Broader tailwinds from Jim Cramer's bullish biotech call and health care's continued sector leadership added momentum, with the XLV healthcare ETF holding steady.

3.7398

July 9, 2026Moderna shares tumbled sharply, giving back a significant portion of their recent 70%+ surge, as a broad risk-off selloff — triggered by President Trump declaring the U.S.-Iran ceasefire 'over' and sending oil prices surging 5%+ — weighed on speculative and high-beta names. The pullback comes despite Moderna trading near a fresh 52-week high and carrying strong recent momentum from its June Science Day pipeline expansion, a unanimous FDA advisory committee vote backing its mRNA flu vaccine mFlusiva, and Jim Cramer flagging biotech as 'the hottest group in the market.' However, Wall Street remains deeply skeptical: Bank of America reiterated a Sell rating today, Morgan Stanley raised its target only to $39, and the consensus 'Reduce' rating with an average target of ~$38 stands in stark contrast to where shares had been trading. Insider selling and the geopolitical macro shock appear to have accelerated profit-taking in the stock.

-7.484

Simply Wall Street · July 18, 2026Does Moderna’s (MRNA) New mRNA-4200 Trial Quietly Rebalance Its Long-Term Oncology Risk Profile?ad-hoc-news.de · July 17, 2026Moderna stock trades steadily as mRNA pipeline and COVID revenues shape outlookStock Titan · July 16, 2026Moderna Trial Tests Cancer Therapy Encoding Seven AntigensReuters · July 15, 2026Sanofi sues Pfizer, Moderna over COVID shot technologyBloomberg Law News · July 15, 2026Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent RoyaltiesSTAT · June 29, 2026Moderna co-founder Kenneth Chien on the future of mRNA — and ModernaInfectious Disease Advisor · June 27, 2026FDA Panel Backs Moderna’s mRNA-Based Influenza Vaccine for Adults 50+Stock Titan · June 17, 2026Moderna spotlights mRNA, AI and robotics at 2026 'Science Day'
Benzinga · July 16, 2026Moderna Doses First US Participant In Its Phase 1 Study Of mRNA-4200, Tumor-Targeted Cancer Antigen Therapy Candidate, For Advanced Or Metastatic Solid Tumors
Mt Newswire · July 13, 2026Jefferies Adjusts Price Target on Moderna to $60 From $53, Maintains Hold Rating
Mt Newswire · July 9, 2026UK Life Sciences Hits GBP3 Billion Investment Milestone
Benzinga · July 8, 2026Morgan Stanley Maintains Equal-Weight on Moderna, Raises Price Target to $39
Benzinga · July 7, 2026RBC Capital Maintains Sector Perform on Moderna, Raises Price Target to $45
Mt Newswire · July 7, 2026Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says
Mt Newswire · July 7, 2026BofA Adjusts Price Target on Moderna to $38 From $34, Maintains Underperform Rating
Mt Newswire · July 7, 2026RBC Capital Adjusts Moderna Price Target to $45 From $38, Maintains Sector Perform Rating

Peers

S&P 500SPX · $7,457.69-1.01%BioNTech SEBNTX · $91.48-0.09%Novavax, Inc.NVAX · $8.21-0.36%Pfizer Inc.PFE · $25.05-0.36%AstraZeneca PLCAZN · $168.90-0.23%Regeneron Pharmaceuticals, Inc.REGN · $676.69-0.33%Amgen Inc.AMGN · $366.29-1.42%Gilead Sciences, Inc.GILD · $134.28-1.48%Vertex Pharmaceuticals IncorporatedVRTX · $485.65-0.08%AbbVie Inc.ABBV · $254.49+0.04%CRISPR Therapeutics AGCRSP · $47.78-1.63%SanofiSNY · $44.66+1.02%